Difference between revisions of "Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][unchecked revision]
(updating cgc reference)
Line 1: Line 1:
 
{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}
 
{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}
  
−
'''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''.  This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong clinical significance in major types of renal cell neoplasia.  Table derived from Liu et al., 2020 [PMID: 32434132] with permission from Cancer Genetics.
+
'''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''.  This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong clinical significance in major types of renal cell neoplasia.  Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.
 
{| class="wikitable"
 
{| class="wikitable"
 
| colspan="8" |'''WHO Classification'''
 
| colspan="8" |'''WHO Classification'''
Line 344: Line 344:
 
==Reference==
 
==Reference==
  
−
1. Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna R, Quintero-Rivera F, Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G. (2018). Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet [Epub ahead of print], PMID 30344013.
+
1. Liu YJ, Houldsworth J, Emmadi R, Dyer L, Wolff DJ. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. Cancer Genet. 2020 Jun;244:40-54. doi: 10.1016/j.cancergen.2020.04.004. Epub 2020 May 1. PMID 32434132.
 
<references />
 
<references />

Revision as of 23:53, 14 January 2021


Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review). This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.

WHO Classification
Subtype Clear Cell RCC Papillary RCC

Type 1

Papillary RCC

Type 2

(heterogeneous group)

MiTF-Translocation RCC Chromophobe RCC Oncocytoma
Percentage 70-75% 15-20% 15-20% 1-5% 5% 5%
Origin Proximal    Tubules Collecting   Ducts
Copy Number Alterations [level of evidencea; clinical significanceb]
Whole genome Mostly gains Mostly losses No CNAs (~50%) [1; R]
chr1 1p- (10%) [2; R] 1p- (25%) [2; R] 1p- (30%) [3; R] -1 (90%) [1; D]c -1/1p- soly (50%) [1; R]
chr2 +2 (18%) [2; R] -2 (80%) [1; D]c
chr3 -3/3p- (VHL, KDM6A,

KDM5C, SETD2, PBRM1)

(90%) [1; D]

+3 (40%) [2; R] 3p-/cnLOH(3p) (21%) [2; R], 3p+ (12%) [3; R], 3q+ (21%) [3; R] -3 (25%) [3; R]
chr4 4p- (10%) [2; R] -4 (21%) [3; R] +4 (10%) [3; R]
chr5 5p+ (24%) [2; R],

5q+ (SQSTM1) (40-60%) [2; R]

5q+/+5 (20%) [2; R] -5 (25%) [3; R]
chr6 6q- (20%) [2; R] -6 (17%) [3; R] 6p21 (TFEB) amp [2; D, P] -6 (90%) [1; D]c
chr7 +7 (25%) [2; R] +7/+7,+7 (84%) [1; D]c +7 (25%) [1; D] +7 (30%) [3; R]
chr8 8p- (25%) [2; R] +8 (MYC) (10-33%) [3; R] -8 (15%) [3; R]c
chr9 9p- (20%) [1; P]

9q- (20%) [2; R]

9p- (19%) [2; R],

9q- (17%) [3; R]

9p- (30%) [3; R] -9 (35%) [3; R]
chr10 10q- (10%) [2; R] 10q- (17%) [3; R] -10 (90%) [1; D]c
chr11 11q- (19%) [3; R] -11 (10%) [3; R]
chr12 +12 (15%) [2; R] +12 (52%) [2; R] +12 (15%) [3; R] +12 (35%) [3; R]
chr13 +13 (13%) [2; R] -13 (20%) [3; R] -13 (85%) [1; D]c
chr14 14q- (HIF1A) (40%) [1; P] -14 (28%) [2; R] -14 (10%) [2; R]
chr15 -15 (15%) [3; R] -15 (15%) [3; R]
chr16 16p+ (12%) [2; R],

16q+ (10%) [2; R]

+16 (55%) [2; R] 16p+ (40%) [2; R],

16q+ (35%) [2; R]

chr17 +17 (84%) [1; D] c 17p- (8%) [3; R],

+17/17q+ (50%) [1; D]

17p- (20%) [3; R],

17q+ (40%) [3; R]

-17 (90%) [1; D]c
chr18 -18 (10%) [2; R] -18 (26%) [2; R] -18 (15%) [3; R]
chr19
chr20 +20 (13%) [2; R] +20 (40%) [2; R]
chr21 -21 (19%) [3; R] -21 (70%) [1; D]c -21 (15%) [3; R]
chr22 -22 (40%) [2; R]
X -X (10%) [3;R]
Y -Y (40%) [1; R with -1]c
Rearrangements [level of evidence; clinical significance]
TERT promoter (5p15) (<10%) [3; R] TFE3 (Xp11), TFEB (6p21) (100%) [1; D, P] TERT promoter (5p15) (12%) [3; R] CCND1 (11q13) (40%) [2; D]
Mutations (SNVs, Indels) [level of evidence; clinical significance]
Mutated

in >20%

PBRM1 [2; R], VHL (also promoter methylation) [1; D] TP53 [2; R]
Mutated

in 10-20%

BAP1 [1; P], SETD2 [2; R] MET [1; D]
Mutated

in 5-10%

KDM5C, MTOR, PTEN, TP53 [2; R] CDKN2A (also promoter hypermethylation) [2; P], MET [1; D] PTEN [2; R]
Mutated

in 2-5%

ARID1A, CDKN2A, KDMT2C/KDMT2D, LRP1B, PIK3CA, PTEN, STAG2, TCEB1, TERT CDKN2A/CDKN2B, KDM6A, MLL3, NF2, NFE2L2, SMARCB1, TERT BAP1, FAT1, KDM6A, NF2, NFE2L2, PBRM1, SETD2, STAG2, TERT, TP53 ARID1A, FAAH2, FAT1/FAT4, FLT4, MICALCL, NIN, PDHB, PDXDC1, TSC1/TSC2, ZNF765 ERCC2, C2CD4C
Mitochondrial  DNA MT-ND5 [3,D] MT-COX1, MT-COX2, MT-COX3, MT-ND5, MT-CYTB [2,D]
Germline susceptibility
Germline susceptibility § mainly VHL (von Hippel-Lindau Syndrome)

§ PTEN (Cowden Syndrome)

§ FLCN (Birt-Hogg-Dube syndrome)

§ TSC1 and TSC2 (tuberous sclerosis)

§ SDHB (most common), SDHC (less common), SDHA (rare), SDHD (rare) (succinate dehydrogenase deficient RCC)

§ MET (Hereditary papillary RCC) § FH (Hereditary leiomyomatosis and RCC) FCLN (Birt-Hogg-Dube syndrome) FCLN (Birt-Hogg-Dube syndrome)
References [9[1], 14[2], 17[3], 24[4], 27[5], 29[6], 32[7], 35[8], 49[9], 156-168[10][11][12][13][14][15][16][17][18][19][20][21][22]] [10[23], 42[24], 67-71[25][26][27][28][29], 73[30], 74[31], 98[32], 169-174[33][34][35][36][37][38]] [10[1], 121[39], 122[40], 124[41], 125[42], 175[43]] [11[44], 12[45], 103[46], 105[47], 106[48], 108[49], 109[50], 129[51], 137[52], 176[53], 177[54]] [12[45], 76[55], 102[56], 103[46], 105[47], 129[51], 132[57], 135-137[58][59][52], 140[60], 178-180[61][62][63]]

Note: a level of evidence (ranges from level 1 to 3 as specified in the methods). Level 1, established clinical significance and present in current WHO classification and/or professional practice guidelines such as NCCN, ASCO, CAP guidelines or FDA approval; Level 2, recurrent clinical significance based on large studies with outcomes; and Level 3, recurrent but uncertain clinical significance based on smaller studies and multiple case reports.

          b clinical significance, D-diagnosis, P-prognosis, R-recurrence

          c alterations in combination

Reference

1. Liu YJ, Houldsworth J, Emmadi R, Dyer L, Wolff DJ. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. Cancer Genet. 2020 Jun;244:40-54. doi: 10.1016/j.cancergen.2020.04.004. Epub 2020 May 1. PMID 32434132.

  1. ↑ 1.0 1.1 Cancer Genome Atlas Research Network (2013-07-04). "Comprehensive molecular characterization of clear cell renal cell carcinoma". Nature. 499 (7456): 43–49. doi:10.1038/nature12222. ISSN 1476-4687. PMC 3771322. PMID 23792563.
  2. ↑ Klatte, Tobias; et al. (2009-02-10). "Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 27 (5): 746–753. doi:10.1200/JCO.2007.15.8345. ISSN 1527-7755. PMID 19124809.
  3. ↑ Mitchell, Thomas J.; et al. (04 19, 2018). "Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal". Cell. 173 (3): 611–623.e17. doi:10.1016/j.cell.2018.02.020. ISSN 1097-4172. PMC 5927631. PMID 29656891. Check date values in: |date= (help)
  4. ↑ Chen, Meng; et al. (2009-11-15). "Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays". International Journal of Cancer. 125 (10): 2342–2348. doi:10.1002/ijc.24642. ISSN 1097-0215. PMC 2768265. PMID 19521957.
  5. ↑ Gerlinger, Marco; et al. (2012-03-08). "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing". The New England Journal of Medicine. 366 (10): 883–892. doi:10.1056/NEJMoa1113205. ISSN 1533-4406. PMC 4878653. PMID 22397650.
  6. ↑ Sato, Yusuke; et al. (2013-08). "Integrated molecular analysis of clear-cell renal cell carcinoma". Nature Genetics. 45 (8): 860–867. doi:10.1038/ng.2699. ISSN 1546-1718. PMID 23797736. Check date values in: |date= (help)
  7. ↑ Beroukhim, Rameen; et al. (2009-06-01). "Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney". Cancer Research. 69 (11): 4674–4681. doi:10.1158/0008-5472.CAN-09-0146. ISSN 1538-7445. PMC 2745239. PMID 19470766.
  8. ↑ Arai, Eri; et al. (2008-09-01). "Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 14 (17): 5531–5539. doi:10.1158/1078-0432.CCR-08-0443. ISSN 1078-0432. PMID 18765545.
  9. ↑ Kroeger, Nils; et al. (2013-04-15). "Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma". Cancer. 119 (8): 1547–1554. doi:10.1002/cncr.27947. ISSN 1097-0142. PMID 23335244.
  10. ↑ Crino, Peter B.; et al. (2006-09-28). "The tuberous sclerosis complex". The New England Journal of Medicine. 355 (13): 1345–1356. doi:10.1056/NEJMra055323. ISSN 1533-4406. PMID 17005952.
  11. ↑ Dalgliesh, Gillian L.; et al. (2010-01-21). "Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes". Nature. 463 (7279): 360–363. doi:10.1038/nature08672. ISSN 1476-4687. PMC 2820242. PMID 20054297.
  12. ↑ Kaimakliotis, Hristos Z.; et al. (2014-05). "Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes". Urology. 83 (5): 1112–1116. doi:10.1016/j.urology.2013.12.035. ISSN 1527-9995. PMID 24582117. Check date values in: |date= (help)
  13. ↑ Kaku, Haruki; et al. (2004-07). "Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma". Urology. 64 (1): 176–181. doi:10.1016/j.urology.2004.03.015. ISSN 1527-9995. PMID 15245966. Check date values in: |date= (help)
  14. ↑ Kluzek, Katarzyna; et al. (2017-04-25). "Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA". Oncotarget. 8 (17): 28558–28574. doi:10.18632/oncotarget.15331. ISSN 1949-2553. PMC 5438672. PMID 28212566.
  15. ↑ Köhn, Linda; et al. (2015-05). "Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma". Applied immunohistochemistry & molecular morphology: AIMM. 23 (5): 334–342. doi:10.1097/PAI.0000000000000087. ISSN 1533-4058. PMC 4431677. PMID 24992170. Check date values in: |date= (help)
  16. ↑ Latif, F.; et al. (1993-05-28). "Identification of the von Hippel-Lindau disease tumor suppressor gene". Science (New York, N.Y.). 260 (5112): 1317–1320. doi:10.1126/science.8493574. ISSN 0036-8075. PMID 8493574.
  17. ↑ Moore, L. E.; et al. (2012-06-25). "Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation". Oncogenesis. 1: e14. doi:10.1038/oncsis.2012.14. ISSN 2157-9024. PMC 3412648. PMID 23552698.
  18. ↑ Peña-Llopis, Samuel; et al. (2012-06-10). "BAP1 loss defines a new class of renal cell carcinoma". Nature Genetics. 44 (7): 751–759. doi:10.1038/ng.2323. ISSN 1546-1718. PMC 3788680. PMID 22683710.
  19. ↑ Piva, Francesco; et al. (2015). "BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies". Expert Review of Molecular Diagnostics. 15 (9): 1201–1210. doi:10.1586/14737159.2015.1068122. ISSN 1744-8352. PMID 26166446.
  20. ↑ Rechsteiner, Markus P.; et al. (2011-08-15). "VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations". Cancer Research. 71 (16): 5500–5511. doi:10.1158/0008-5472.CAN-11-0757. ISSN 1538-7445. PMID 21715564.
  21. ↑ Ricketts, Christopher J.; et al. (2012-12). "Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer". The Journal of Urology. 188 (6): 2063–2071. doi:10.1016/j.juro.2012.08.030. ISSN 1527-3792. PMC 3856891. PMID 23083876. Check date values in: |date= (help)
  22. ↑ Zhang, Zhongfa; et al. (2010). "A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression". Advances in Bioinformatics: 428325. doi:10.1155/2010/428325. ISSN 1687-8035. PMC 2909727. PMID 20671976.
  23. ↑ Cancer Genome Atlas Research Network; et al. (2016-01-14). "Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma". The New England Journal of Medicine. 374 (2): 135–145. doi:10.1056/NEJMoa1505917. ISSN 1533-4406. PMC 4775252. PMID 26536169.
  24. ↑ Antonelli, Alessandro; et al. (2010-06). "Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma". Cancer Genetics and Cytogenetics. 199 (2): 128–133. doi:10.1016/j.cancergencyto.2010.02.013. ISSN 1873-4456. PMID 20471516. Check date values in: |date= (help)
  25. ↑ Jiang, F.; et al. (1998-11). "Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes". The American Journal of Pathology. 153 (5): 1467–1473. doi:10.1016/S0002-9440(10)65734-3. ISSN 0002-9440. PMC 1853413. PMID 9811338. Check date values in: |date= (help)
  26. ↑ Klatte, Tobias; et al. (2009-02-15). "Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 15 (4): 1162–1169. doi:10.1158/1078-0432.CCR-08-1229. ISSN 1078-0432. PMID 19228721.
  27. ↑ Sanders, Melinda E.; et al. (2002-09). "Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma". The American Journal of Pathology. 161 (3): 997–1005. doi:10.1016/S0002-9440(10)64260-5. ISSN 0002-9440. PMC 1867241. PMID 12213728. Check date values in: |date= (help)
  28. ↑ Yu, Wenjuan; et al. (2013-06). "Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information". Acta Histochemica. 115 (5): 452–459. doi:10.1016/j.acthis.2012.10.009. ISSN 1618-0372. PMID 23219441. Check date values in: |date= (help)
  29. ↑ Schraml, P.; et al. (2000-03). "Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma". The Journal of Pathology. 190 (4): 457–461. doi:10.1002/(SICI)1096-9896(200003)190:43.0.CO;2-C. ISSN 0022-3417. PMID 10699995. Check date values in: |date= (help)
  30. ↑ Hughson, M. D.; et al. (1998-10-15). "Clear-cell and papillary carcinoma of the kidney: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification, cytogenetics, and fluorescence in situ hybridization". Cancer Genetics and Cytogenetics. 106 (2): 93–104. doi:10.1016/s0165-4608(98)00068-5. ISSN 0165-4608. PMID 9797772.
  31. ↑ Velickovic, M.; et al. (2001-06-15). "VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance". Cancer Research. 61 (12): 4815–4819. ISSN 0008-5472. PMID 11406557.
  32. ↑ Przybycin, Christopher G.; et al. (2013-07). "Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens". Advances in Anatomic Pathology. 20 (4): 245–263. doi:10.1097/PAP.0b013e318299b7c6. ISSN 1533-4031. PMID 23752087. Check date values in: |date= (help)
  33. ↑ Hes, Ondrej; et al. (2006-06). "Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases". Annals of Diagnostic Pathology. 10 (3): 133–139. doi:10.1016/j.anndiagpath.2005.12.002. ISSN 1092-9134. PMID 16730306. Check date values in: |date= (help)
  34. ↑ Lefèvre, Marine; et al. (2005-12). "Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases". The American Journal of Surgical Pathology. 29 (12): 1576–1581. doi:10.1097/01.pas.0000184821.09871.ec. ISSN 0147-5185. PMID 16327429. Check date values in: |date= (help)
  35. ↑ Jones, Timothy D.; et al. (2005-10-15). "Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 11 (20): 7226–7233. doi:10.1158/1078-0432.CCR-04-2597. ISSN 1078-0432. PMID 16243792.
  36. ↑ Sweeney, Paul; et al. (2002-07). "Biological significance of c-met over expression in papillary renal cell carcinoma". The Journal of Urology. 168 (1): 51–55. ISSN 0022-5347. PMID 12050491. Check date values in: |date= (help)
  37. ↑ Kattar, M. M.; et al. (1997-11). "Clinicopathologic and interphase cytogenetic analysis of papillary (chromophilic) renal cell carcinoma". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 10 (11): 1143–1150. ISSN 0893-3952. PMID 9388066. Check date values in: |date= (help)
  38. ↑ Kovacs, G.; et al. (1991-07). "Cytogenetics of papillary renal cell tumors". Genes, Chromosomes & Cancer. 3 (4): 249–255. doi:10.1002/gcc.2870030403. ISSN 1045-2257. PMID 1958590. Check date values in: |date= (help)
  39. ↑ Mendel, Lionel; et al. (03 2018). "Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome". Genes, Chromosomes & Cancer. 57 (3): 99–113. doi:10.1002/gcc.22513. ISSN 1098-2264. PMID 29127730. Check date values in: |date= (help)
  40. ↑ Skala, Stephanie L.; et al. (01 2018). "Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 31 (1): 179–197. doi:10.1038/modpathol.2017.99. ISSN 1530-0285. PMID 28840857. Check date values in: |date= (help)
  41. ↑ Pan, Chin-Chen; et al. (2013-07). "High chromosomal copy number alterations in Xp11 translocation renal cell carcinomas detected by array comparative genomic hybridization are associated with aggressive behavior". The American Journal of Surgical Pathology. 37 (7): 1116–1119. doi:10.1097/PAS.0b013e318293d872. ISSN 1532-0979. PMID 23759936. Check date values in: |date= (help)
  42. ↑ Malouf, Gabriel G.; et al. (2013-09-01). "Genomic heterogeneity of translocation renal cell carcinoma". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 19 (17): 4673–4684. doi:10.1158/1078-0432.CCR-12-3825. ISSN 1557-3265. PMC 3882157. PMID 23817689.
  43. ↑ Argani, Pedram; et al. (11 2016). "TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity". The American Journal of Surgical Pathology. 40 (11): 1484–1495. doi:10.1097/PAS.0000000000000720. ISSN 1532-0979. PMC 5069163. PMID 27565001. Check date values in: |date= (help)
  44. ↑ Davis, Caleb F.; et al. (2014-09-08). "The somatic genomic landscape of chromophobe renal cell carcinoma". Cancer Cell. 26 (3): 319–330. doi:10.1016/j.ccr.2014.07.014. ISSN 1878-3686. PMC 4160352. PMID 25155756.
  45. ↑ 45.0 45.1 Chen, Fengju; et al. (2016-03-15). "Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma". Cell Reports. 14 (10): 2476–2489. doi:10.1016/j.celrep.2016.02.024. ISSN 2211-1247. PMC 4794376. PMID 26947078.
  46. ↑ 46.0 46.1 Krill-Burger, John M.; et al. (2012-06). "Renal cell neoplasms contain shared tumor type-specific copy number variations". The American Journal of Pathology. 180 (6): 2427–2439. doi:10.1016/j.ajpath.2012.01.044. ISSN 1525-2191. PMC 3378847. PMID 22483639. Check date values in: |date= (help)
  47. ↑ 47.0 47.1 Yusenko, Maria V.; et al. (2009-05-18). "High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas". BMC cancer. 9: 152. doi:10.1186/1471-2407-9-152. ISSN 1471-2407. PMC 2686725. PMID 19445733.
  48. ↑ Kang, Xue-Ling; et al. (2015). "Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization". International Journal of Clinical and Experimental Pathology. 8 (4): 3636–3647. ISSN 1936-2625. PMC 4466932. PMID 26097545.
  49. ↑ Sperga, Maris; et al. (2013-10). "Chromophobe renal cell carcinoma--chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases". Virchows Archiv: An International Journal of Pathology. 463 (4): 563–573. doi:10.1007/s00428-013-1457-6. ISSN 1432-2307. PMID 23913167. Check date values in: |date= (help)
  50. ↑ Casuscelli, Jozefina; et al. (2017-06-15). "Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma". JCI insight. 2 (12). doi:10.1172/jci.insight.92688. ISSN 2379-3708. PMC 5470887. PMID 28614790.
  51. ↑ 51.0 51.1 Gowrishankar, Banumathy; et al. (2014-12). "Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization". BJU international. 114 (6): 881–890. doi:10.1111/bju.12643. ISSN 1464-410X. PMC 4257075. PMID 24467611. Check date values in: |date= (help)
  52. ↑ 52.0 52.1 Tan, Min-Han; et al. (2010-05-12). "Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma". BMC cancer. 10: 196. doi:10.1186/1471-2407-10-196. ISSN 1471-2407. PMC 2883967. PMID 20462447.
  53. ↑ Abbosh, Philip; et al. (12 2018). "Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer". European Urology Focus. 4 (6): 969–971. doi:10.1016/j.euf.2017.01.003. ISSN 2405-4569. PMID 28753842. Check date values in: |date= (help)
  54. ↑ Hammer, B. E. (1989-03). "Proton decoupled 13C NMR imaging". Magnetic Resonance Imaging. 7 (2): 235–240. doi:10.1016/0730-725x(89)90710-8. ISSN 0730-725X. PMID 2541301. Check date values in: |date= (help)
  55. ↑ Durinck, Steffen; et al. (2015-01). "Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes". Nature Genetics. 47 (1): 13–21. doi:10.1038/ng.3146. ISSN 1546-1718. PMC 4489427. PMID 25401301. Check date values in: |date= (help)
  56. ↑ Gowrishankar, Banumathy; et al. (2015-05). "A genomic algorithm for the molecular classification of common renal cortical neoplasms: development and validation". The Journal of Urology. 193 (5): 1479–1485. doi:10.1016/j.juro.2014.11.099. ISSN 1527-3792. PMID 25498568. Check date values in: |date= (help)
  57. ↑ Joshi, Shilpy; et al. (2015-12-01). "The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis". Cell Reports. 13 (9): 1895–1908. doi:10.1016/j.celrep.2015.10.059. ISSN 2211-1247. PMC 4779191. PMID 26655904.
  58. ↑ Lindgren, Valerie; et al. (2004-02). "Cytogenetic analysis of a series of 13 renal oncocytomas". The Journal of Urology. 171 (2 Pt 1): 602–604. doi:10.1097/01.ju.0000109172.07081.16. ISSN 0022-5347. PMID 14713769. Check date values in: |date= (help)
  59. ↑ Paner, Gladell P.; et al. (2007-01). "High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies". Archives of Pathology & Laboratory Medicine. 131 (1): 81–85. doi:10.1043/1543-2165(2007)131[81:HIOCAI]2.0.CO;2. ISSN 1543-2165. PMID 17227127. Check date values in: |date= (help)
  60. ↑ Boris, Ronald S.; et al. (2011-06). "The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma". The Journal of Urology. 185 (6): 2050–2055. doi:10.1016/j.juro.2011.02.051. ISSN 1527-3792. PMC 3164767. PMID 21496834. Check date values in: |date= (help)
  61. ↑ Michalova, Kvetoslava; et al. (2018-08). "Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases". Annals of Diagnostic Pathology. 35: 1–6. doi:10.1016/j.anndiagpath.2018.01.010. ISSN 1532-8198. PMID 30072012. Check date values in: |date= (help)
  62. ↑ He, Huiying; et al. (2018-12). ""High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases". Virchows Archiv: An International Journal of Pathology. 473 (6): 725–738. doi:10.1007/s00428-018-2456-4. ISSN 1432-2307. PMID 30232607. Check date values in: |date= (help)
  63. ↑ Dvorakova, Marie; et al. (2010-05-24). "Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up". Diagnostic Pathology. 5: 32. doi:10.1186/1746-1596-5-32. ISSN 1746-1596. PMC 2881070. PMID 20497539.
Retrieved from "https://ccga.io/index.php?title=Renal_Cell_Neoplasia_Tables:_Recurrent_Cytogenomic_Alterations&oldid=9314"